CuraGen
Executive Summary
Exploiting technology from Yale and Cornell Universities, CuraGen Corp. is pursuing novel methods that may address the problem of isolating the genes and expressed proteins that are responsible for a number of complex disease states. Through its {Quantitative Expression Analysis} technique, Curagen can screen a sample of diseased tissue for the identity of the genes in the sample and the rate of those genes' expression.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.